Update on the Neuropathological Diagnosis of Frontotemporal Dementias
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Previous criteria for Frontotemporal Dementia have primarily been designed for research purposes (1–5). An international group of experts on clinical and neuropathological aspects of frontotemporal dementia (FTD) recently re-assessed criteria for the diagnosis of FTD at a meeting entitled “The Frontotemporal Dementia and Pick's Disease Criteria Conference” held at the National Institutes of Health in Bethesda, MD on July 7, 2000 (see ref #1 and the roster of meeting participants in the Acknowledgments). Building upon a substantial literature on these disorders, the goal of the conference was to update previous FTD diagnostic criteria, taking into account recent research advances to refine guidelines for the clinical and neuropathological diagnosis of FTD (1). Here we provide a brief overview of the most salient points of the neuropathology recommendations for disorders included among FTDs. Although Pick's disease can be considered the prototype of FTDs, in the last 3 decades it became increasingly clear to several research groups that there were a number of other distinct FTD variants that lacked the lobar atrophy and related neuropathology of Pick's disease (1). This prompted the use of a number of different names to designate these disorders, including FTD, frontal lobe degeneration of the non-Alzheimer-type, frontotemporal lobar degeneration (FTLD), dementia lacking distinct histopathology (DLDH), progressive aphasia and semantic dementia (1). Moreover, since several kindreds with FTD and parkinsonism linked to chromosome 17 were shown to have pathogenic tau gene mutations, the term FTDP-17 was used to refer to this hereditary group of FTDs, while a less well-characterized disorder in other patients with evidence of FTD as well as clinical and pathological findings of motor neuron disease (MND) has been designated FTD with MND, and hereditary forms of this disease have been linked to chromosome 9 (1). Since these and other terms have been used to refer to FTDs, thereby leading to a nearly impenetrable nomenclature, conference participants recommended that FTD be used as the clinical diagnostic term for these disorders, while FTLD and the other terms listed in this paper were recommended for the currently known neuropathological variants of FTDs (1). While gross examination of postmortem brain from FTD patients often show frontotemporal atrophy, microscopic and other studies are needed to distinguish FTD variants from Alzheimer disease (AD), dementia with Lewy bodies (DLB), and other disorders (Fig. 1). The brain regions to be examined as well as the most relevant diagnostic methods are described in the conference report and previous citations therein (1). Notably, it was recommended that traditional histochemical methods be complemented by more sensitive immunohistochemical techniques to detect tau pathology, as well as by immunohistochemistry for ubiquitin since some lesions in FTDs are negative for tau yet positive for ubiquitin (1). Similarly, other diagnostically relevant pathologies (e.g. ballooned or achromatic neurons) are most effectively detected by immunostaining with antibodies to neurofilament or alpha-B-crystallin proteins, and the same applies to Lewy bodies (LBs) and related lesions in neurodegenerative synucleinopathies that require the use of antibodies to alpha-synuclein (1), though other techniques also may assist in establishing a diagnosis of FTD subtypes. For example, Western blot analyses of tau proteins separate disorders into those with and without insoluble tau, and the profile of insoluble tau differentiates those with a predominance of 3 microtubule-binding repeats (3R tau), 4 microtubule-binding repeats (4R tau), or both 3R and 4R tau (2, 3), while recent studies suggest that FTLD shows reduced soluble tau, no insoluble tau, and normal tau mRNA levels (4). Composite figure showing representative macroscopic (a–e) and microscopic (f–p) findings in various FTD subtypes. a: Pick's disease brain showing frontal and temporal lobar atrophy, with less obvious atrophy of inferior parietal lobule and sparing of pre- and post-central gyri, the posterior superior temporal gyrus, and the occipital pole. b: Tangle-only dementia brain exhibiting selective atrophy of the hippocampus (arrow) and medial temporal lobe (coronal section at level of mammillary body). c: FTLD (DLDH) brain with marked atrophy of the head of the caudate nucleus (arrow) and marked hydrocephalus (coronal section are level of optic chiasm). d: CBD brain demonstrating circumscribed atrophy of the parasagittal superior frontal gyrus and superior parietal lobule, including the pre- and post-central gyri (arrows). e: FTLD with motor neuron disease brain characterized by atrophy of the pre-central gyrus (arrow) with preservation of the post-central gyrus, while the temporal and frontal lobes also show atrophy. f–i: 3R tauopathy. f: Pick's disease—the dentate fascia shows neuronal loss and inclusions visible with routine his
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Self-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Cited by
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citationA new subtype of frontotemporal lobar degeneration with FUS pathology
Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H. A., & Mackenzie, I. R. A. (2009) · Brain · doi:10.1093/brain/awp214 · Cited by 722
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724
“Biochemical analysis of tau protein is clearly beyond the realm of most neurohistology laboratories, but can add information that is supportive of a diagnosis of CBD (83) and is a useful means of classifying non-Alzheimer neurodegenerative disorders (78).”
BackgroundSelf-citationNeuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Frontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 501
Metadata
- Authors
- Trojanowski, J. Q., & Dickson, D.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-12
- Volume
- 60
- Issue
- 12
- Pages
- 1123-1126
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2413259662
- Cited by
- 87
- References
- 3
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the Neuropathological Diagnosis of Frontotemporal Dementias. https://app.cochat.ai/papers/10.1093/jnen/60.12.1123
- The paper
- Trojanowski, J. Q., & Dickson, D. (2001). Update on the Neuropathological Diagnosis of Frontotemporal Dementias. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/60.12.1123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.